Data-independent acquisition

Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

Retrieved on: 
Thursday, May 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, ASMS, CSF, Data analysis, Software, American Society for Mass Spectrometry, Fish acute toxicity syndrome, Yale School of Medicine, Machine learning, Proteome, University of Copenhagen, Proteomics, Patient, Environment, Mass spectrometry, SLE, Solution, Buck, Health, GLP, Johns Hopkins University, HRM, Society, Lupus, Trial of the century, AD, Research, Algorithm, Buck Institute for Research on Aging, Plasma, Conference, DIA, CDK, University, Biomarker, Drug development, ACS Chemical Biology, Protein, Proteoform, Drug discovery, Acquisition, Artificial intelligence, Data-independent acquisition, GCP, AstraZeneca, Body fluid, Medical imaging, Pharmaceutical industry, Fine chemical, Online shopping

Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.

Key Points: 
  • Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration.
  • Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics, said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys.
  • "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.
  • At this years ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars.

Biognosys and NeoGenomics Expand Global Strategic Partnership Initiatives on Multiple Discovery Proteomics Solutions Supporting Biopharma R&D

Retrieved on: 
Monday, April 11, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical Devices, Clinical Trials, Company, Drug development, Compugen (Israeli company), Biomarker, MIF, CLIA, DIA, Immunotherapy, NeoGenomics, Patient, GLP, AACR, Research, Proteome, Environment, American Association, Proteoform, Cancer, Norwich Pharma Services, Health, NEO, Marie Cassidy, Laboratory, Software, Association, CAP, GCP, Oncology, HRM, Nasdaq, Melanoma, Physician, Drug discovery, Solution, Information services, Data-independent acquisition, Protein, Proteomics, Partnership, Medical imaging, Pharmaceutical industry

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.

Key Points: 
  • Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today a global strategic partnership agreement with NeoGenomics, Inc. (Nasdaq: NEO), a leading provider of oncology testing and global contract research services.
  • The strategic partnership will encompass multiple strategic and commercial initiatives, including NeoGenomics labs offering access to Biognosys proteomics platforms, medical and scientific affairs-joint presentations and discussions, along with joint scientific and technical initiatives.
  • At Biognosys, we continuously push the boundaries of what is possible with our proteomics solutions to address key challenges in drug development, said Kristina Beeler, Ph.D., Chief Business Officer, Biognosys.
  • We are excited to now combine our proteomics platforms with NeoGenomics immuno-profiling platform to advance our biopharma partners oncology drug development programs.

Biognosys Presenting Data on its TrueDiscovery™ and TrueTarget™ Proteomics Platforms at the AACR Annual Meeting 2022

Retrieved on: 
Thursday, March 31, 2022
Oncology, Health, Medical Devices, Research, Science, Pharmaceutical, Biotechnology, Drug development, DIA, NeoGenomics, GLP, CDK9, AACR, Research, Proteome, American Association, Environment, Proteoform, Health, EGFR, Software, Association, American Association for Cancer Research, BRD4, GCP, HRM, Drug discovery, Fish acute toxicity syndrome, Solution, Efficiency, Data-independent acquisition, Protein, Proteomics, Disease, Pharmaceutical industry, Online shopping, Fine chemical, TRUEDISCOVERY™, TRUETARGET™, BIOGNOSYS

The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery and TrueTarget.

Key Points: 
  • The company will be presenting a talk and five scientific posters around two of its major service platforms, TrueDiscovery and TrueTarget.
  • Our AACR data shows how Biognosys has been able to establish mass spectrometry-based proteomics technology to provide detailed and unbiased insights about the proteome.
  • The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.
  • TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced Data Independent Acquisition (DIA)-based protein quantification technology co-invented and patented by Biognosys.